FY2027 Earnings Estimate for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD) – Analysts at HC Wainwright dropped their FY2027 earnings per share (EPS) estimates for Invivyd in a research note issued to investors on Tuesday, March 10th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.26) per share for the year, down from their previous forecast of ($0.25). The consensus estimate for Invivyd’s current full-year earnings is ($1.64) per share.

IVVD has been the topic of several other research reports. D. Boral Capital restated a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. BTIG Research reiterated a “buy” rating and set a $10.00 price objective on shares of Invivyd in a report on Thursday, February 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. Finally, Zacks Research upgraded shares of Invivyd from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.00.

Invivyd Stock Down 5.3%

Shares of IVVD opened at $1.80 on Thursday. The business’s fifty day moving average is $1.94 and its 200 day moving average is $1.86. Invivyd has a 12-month low of $0.46 and a 12-month high of $3.07. The stock has a market cap of $508.68 million, a P/E ratio of -3.83 and a beta of 0.61.

Insiders Place Their Bets

In related news, insider Jill Andersen sold 34,939 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total value of $55,203.62. Following the completion of the sale, the insider directly owned 181,736 shares of the company’s stock, valued at approximately $287,142.88. This represents a 16.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO William E. Duke sold 20,964 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total value of $33,123.12. Following the transaction, the chief financial officer owned 107,717 shares in the company, valued at approximately $170,192.86. This trade represents a 16.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 227,172 shares of company stock worth $354,534 in the last three months. 25.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Janus Henderson Group PLC boosted its holdings in Invivyd by 28.2% during the fourth quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock worth $80,870,000 after purchasing an additional 7,160,065 shares during the last quarter. Perceptive Advisors LLC purchased a new stake in Invivyd in the 4th quarter valued at about $53,809,000. BVF Inc. IL bought a new position in shares of Invivyd during the 4th quarter worth approximately $48,227,000. RA Capital Management L.P. bought a new position in shares of Invivyd during the 3rd quarter worth approximately $18,831,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Invivyd in the 3rd quarter worth approximately $8,108,000. 70.36% of the stock is owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.